Granted Patent B2

US 12,539,334 · App. 16/961,403 · Granted Feb 3, 2026

Inventor: Tracy Matray (Snohomish, WA)

Assignee: Sony Group Corporation

A61K47/605A61K47/6849A61K47/6851A61K45/06

Abstract

Claims (52)

1 . A compound having the following structure (I):

or a stereoisomer, pharmaceutically acceptable salt or tautomer thereof, wherein:

M is, at each occurrence, independently a biologically active moiety (i) selected from an NSAID, a kinase inhibitor, an anthracycline, and an EGFR inhibitor, or (ii) having one of the following structures:

L comprises a physiologically cleavable linker, wherein L is cleavable: at a pH ranging from 6 to 8, at a temperature ranging from 20° C. to 40° C. or by an enzyme;

L 1 is, at each occurrence, independently an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene or heteroalkynylene linker;

L 2 and L 3 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker;

R 1 is, at each occurrence, independently H, alkyl or alkoxy;

R 2 and R 3 are each independently —H, —OH, —SH, alkyl, alkoxy, alkylether, heteroalkyl, alkylaminyl, alkylcarbonyl, alkoxycarbonyl, Q or a protected form thereof, or L′, wherein the alkyl, alkoxy, alkylether, heteroalkyl, alkylaminyl, alkylcarbonyl and alkyloxycarbonyl are optionally substituted with hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether, or combinations thereof,

R 4 is, at each occurrence, independently OH, SH, O − , S − , OR d or SR d − ;

R 5 is, at each occurrence, independently oxo, thioxo or absent;

R d is a cation;

Q is, at each occurrence, independently a moiety comprising a reactive group, or protected form thereof, capable of forming a covalent bond with a complementary reactive group Q′ on a targeting moiety;

L′ is, at each occurrence, independently a linker comprising a covalent bond to Q, a targeting moiety, a linker comprising a covalent bond to a targeting moiety, a solid support or solid support residue, a linker comprising a covalent bond to a solid support or solid support residue or a linker comprising a covalent bond to a further compound of structure (I);

m is, at each occurrence, independently an integer of zero or greater, provided that at least one occurrence of m is an integer of three or greater; and

n is an integer of one or greater.

2 . The compound of claim 1 , wherein the compound has the following structure (IA):

wherein x 1 and x 2 are, at each occurrence, independently an integer from 0 to 6.

3 . The compound of claim 1 , wherein L 1 is, at each occurrence, independently C 1 -C 6 alkylene or C 2 -C 6 alkynylene.

4 . The compound of claim 1 , wherein the compound has the following structure (IB):

wherein:

x 1 and x 2 are, at each occurrence, independently an integer from 0 to 6; and

y is an integer from 1 to 6.

5 . The compound of claim 1 , wherein R 4 is, at each occurrence, independently OH, O − or OR d , and wherein R 5 is, at each occurrence, oxo.

6 . The compound of claim 1 , wherein the compound has one of the following structures (IB′) or (IB″):

7 . The compound of claim 1 , wherein R 1 is H.

8 . The compound of claim 1 , wherein R 2 and R 3 are each independently OH or —OP(═R a )(R b )R c .

9 . The compound of claim 1 , wherein one of R 2 or R 3 is OH or —OP(═R a )(R b )R c , and the other of R 2 or R 3 is Q or a linker comprising a covalent bond to Q.

10 . The compound of claim 1 , wherein the targeting moiety is an antibody or cell surface receptor antagonist selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a hepatocyte growth factor receptor (HGFR) inhibitor, an insulin-like growth factor receptor (IGFR) inhibitor, a folate, and a MET inhibitor.

11 . The compound of claim 1 , wherein Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, «-haloamide, biotin, amino or a maleimide functional group.

12 . The compound of claim 1 , wherein Q comprises a moiety selected from one of the following structures:

wherein:

X is halo, and

EWG is an electron withdrawing group.

13 . The compound of claim 1 , wherein L is, at each occurrence, independently a linker comprising an amide bond, an ester bond, a disulfide bond, a double bond, a triple bond, an ether bond, a ketone, a diol, a cyano, a nitro or combinations thereof.

14 . The compound of claim 1 , wherein at least one occurrence of M has one of the following structures:

15 . The compound claim 1 , wherein the targeting moiety is an antibody specific for a tumor cell antigen.

16 . A compound of claim 1 , wherein the compound has one of the following structures:

wherein:

N′ has the following structure:

I′ has the following structure:

D′ has the following structure

 and

D″ has the following structure:

17 . A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

18 . The compound of claim 1 , wherein L comprises one of the following structures:

wherein:

R is H, methyl, ethyl, isopropyl, tert-butyl, or phenyl;

X is O or CH 2 ; and

n is an integer greater than 0.

19 . The compound of claim 1 , wherein L-M has one of the following structures:

20 . The compound of claim 18 , wherein L-M has one the following structures:

wherein L 1a and L 1b are each independently optional alkylene or heteroalkylene linkers, and wherein at least one occurrence of L 1a or L 1b is present and has one of the following structures:

Assignments (3)

Continuity (2)

References Cited (400)